Aalst, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Aalst, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Bruxelles, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Bruxelles, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Edegem, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Leuven, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Leuven, Belgium; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Plovdiv, Bulgaria; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Sofia, Bulgaria; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Coquitlam, BC, Canada; Research Site:
A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
Saskatoon, SK, Canada; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Winnipeg, MB, Canada; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Brno, Czech Republic; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Plzen, Czech Republic; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Praha, Czech Republic; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Tallinn, Estonia; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Tallinn, Estonia; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Tartu, Estonia; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Tartu, Estonia; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Paris, France; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Paris, France; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Toulouse, France; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Toulouse, France; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Tours, France; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Tours, France; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Aachen, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Aachen, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Berlin, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Essen, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Hamburg, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Heidelberg, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Heidelberg, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
München, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
München, Germany; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Athens, Greece; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Budapest, Hungary; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Budapest, Hungary; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Pecs, Hungary; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Pecs, Hungary; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Szeged, Hungary; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Szeged, Hungary; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Haifa, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Jerusalem, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Jerusalem, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Petah Tikva, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Petah Tikva, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Ramat Gan, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Ramat Gan, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Tel Aviv, Israel; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Padova, Italy; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Pavia, Italy; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Pavia, Italy; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Roma, Italy; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Kaunas, Lithuania; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Kaunas, Lithuania; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Vilnius, Lithuania; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Vilnius, Lithuania; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Bialystok, Poland; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Lodz, Poland; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Szczecin, Poland; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Warszawa, Poland; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Wroclaw, Poland; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Bucharest, Romania; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Barcelona, Spain; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Madrid, Spain; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Madrid, Spain; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Zürich, Switzerland; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Kiev, Ukraine; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Lugnansk, Ukraine; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Zaporozhye, Ukraine; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Birmingham, United Kingdom; Research Site:
A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
Nottingham, United Kingdom; Research Site:
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.